Curis, Inc.

Good morning and welcome to the QRIS first quarter 2023 business update call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After the company's prepared remarks, call participants will have an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ms. Diantha Duvall, QRIS Chief Financial Officer Ms. Dianza, please go ahead.

Thank you, and welcome to the QRIS first quarter 2023 business update call. Before we begin, I would like to encourage everyone to go to the investor section of our website at www.qris.com to find our first quarter 2023 business update release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements. which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Denser, President and Chief Executive Officer, Bob Martel, Chief Scientific Officer, and Jonathan Zung, our newly appointed Chief Development Officer. We will also be available for a question and answer period at the end of the call. I'd now like to turn the call over to Jim.

Thank you, Diantha. Good afternoon, everyone, and welcome to QRIS's first quarter business update call. This past quarter, we made important progress with our lead clinical candidate, Emma Vucerti. As we mentioned in our March update, we completed enrolling the additional patients requested by FDA ahead of schedule which we believe is indicative of both the clear unmet need in leukemia and the excitement among the clinical community for this novel agent. We are collecting and analyzing data from these patients this quarter and expect to discuss these data with the FDA in the third quarter. We are optimistic that these data will be sufficient for the FDA to allow us to proceed with a recommended phase two dose and move into the expansion phase of our Take Aim leukemia study. We're also enrolling patients with primary central nervous system lymphoma, or PCNSL, and treating them with emavucirtib in combination with the BTK inhibitor ibrutinib in our Take Aim lymphoma study. We believe emavucirtib, in combination with ibrutinib, has the potential to be an important new therapy in PCNSL. which is an orphan population of patients with high unmet need. I'm also pleased to announce the expansion of the QRIS executive team with the addition of Dr. Jonathan Zung as our chief development officer. Dr. Zung strengthens our executive team as a well-respected industry leader with a wealth of drug development experience in both biotech and large pharma. In short, the QRIS team continues to make significant progress in establishing our lead clinical candidate, Emma Hussertib, showing both clear single-agent activity and broad potential in combination therapy as a potential cornerstone treatment in hematological malignancies. And we look forward to sharing the results of our discussions with FDA in the quarter ahead. With that, I'll turn the call back over to Diantha to review our financial results for the quarter. Diantha?